Eisai Projects Major Growth for Alzheimer's Therapy Leqembi
Biogen Partner Eisai Begins FDA Submissions for Injectable Alzheimer's Therapy
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (Lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Eisai Co., Ltd. announced today that Eisai has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA.
Eli Lilly Alzheimer's Therapy Set for June FDA AdCom Meeting
Biogen Says Uptake for Alzheimer's Therapy Is Improving
Biogen's Alzheimer's Drug to Cost $3.5B for Medicare in 2025: Report
European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer's Drug Lecanemab
Biogen Inc (NASDAQ:BIIB) and Eisai Co Ltd (OTC:ESALF) (OTC:ESALY) faced a setback as the much-anticipated Oral Explanation slated for March 19 at the Committee for Medicinal Products for Human Use (CH
Labcorp Expands Alzheimer's Testing Portfolio With New Diagnostic
Esai Gets Japanese Approval for Epilepsy Drug Using Ligand Technology
Biogen Slips as Outlook Disappoints Amid Flat Leqembi Sales
Earnings Call Summary | EISAI CO(ESALF.US) Q3 2023 Earnings Conference
The following is a summary of the Eisai Co Ltd (ESALF) Q3 2023 Earnings Call Transcript:Financial Performance:Eisai reported Q3 revenue of JPY 551.3 billion, a slight increase from the previous year.P
Eisai Co 9-Mos Net Y29.10B Vs Net Y39.11B
Eisai Co. Ltd. (4523.TO) Tokyo Nine Months Ended December 31 GROUP 2023 2022 Revenue Y551.26 bln Y546.20 bln Operating Profit Y37.54 bln
Biogen Slips as UBS Cuts to Neutral on Alzheimer's Drug Uptake
Eisai, Biogen File for EU Marketing Authorization of Alzheimer's Drug
Eisai Wins Chinese Approval for Its Alzheimer's Drug Leqembi
Eisai Co.’s breakthrough therapy for Alzheimer’s disease has been cleared by regulators in China, giving the drugmaker a chance to tap growing demand for medicines to treat the debilitating condition in a rapidly aging population.
Development of a predictive model for amyloid beta accumulation in the brain using a wristband biosensor
I would like to inform you that the National University Corporation Oita University (hereafter Oita University) and Eisai Co., Ltd. (hereafter Eisai) have developed the world's first machine learning model to predict amyloid beta (Aβ, Note 1) accumulation in the brain using a wristband type biosensor.
Biogen, Eisai to Launch New Alzheimer Therapy in Japan
Merck Keytruda Combo Fails in Late-stage Trial for Uterine Cancer
Express News | Merck, Eisai Announced That Phase 3 LEAP-001 Trial Of Keytruda Plus Lenvima Did Not Meet Its Dual Primary Endpoints Of Overall Survival And Progression-Free Survival For The First-line Treatment For Patients With Advanced Or Recurrent Endometrial Cancer
Biogen Swings to Q3 Growth After Reata Acquisition
No Data